Many enterprises in the pharmaceutical circle "get married", is it a group heating or a strong combination?

[industry trends of pharmaceutical network] since the 4 + 7 centralized purchase and medical insurance negotiation this year, the segmentation of pharmaceutical industry has accelerated, and the situation of pharmaceutical enterprises is different The end of the year is a busy stage Some pharmaceutical companies are busy selling houses and selling land, some are busy purchasing.. In recent years, there have been many enterprises "marriage" in the pharmaceutical circle, in order to explore the direction of sustainable development in the future, or to keep warm? Guangteng Pharmaceutical Co., Ltd and guangteng Pharmaceutical Co., Ltd announced on December 26 that the company and guangteng Pharmaceutical Co., Ltd signed a "project cooperation contract" on December 23 The two parties intend to jointly develop and copy chemical drugs, and jointly operate the developed and copied and registered copied drugs, with the relevant rights and interests accounting for 50% respectively The products developed in the early stage include respiratory system, gastrointestinal system and children's medicine field, focusing on the development of new pharmaceutical preparations in these fields, focusing on the development of oral solid and oral liquid sustained-release preparations and related APIs Teyi pharmaceutical said that this project cooperation is conducive to the integration and utilization of their respective resource advantages, in-depth cooperation in the joint research and development of generic drugs, to achieve complementary advantages, mutual benefit and win-win, in line with the overall strategic layout of the company Dongyangguang pharmaceutical & No.1 pharmaceutical recently announced that the company recently signed two strategic cooperation framework agreements with Guangdong No.1 pharmaceutical under 111 group in November and December respectively It is reported that dongyangguang pharmaceutical and No.1 pharmaceutical industry will work closely together to promote the integration of supply and marketing and scale effect, and actively explore a new business model of medical drug patient insurance, so as to promote the benefits of both parties, terminals and consumers The cooperation period of the strategic cooperation framework agreement is three years Ruibo pharmaceutical & Beida Pharmaceutical Co., Ltd on November 18, the signing ceremony of strategic cooperation between Ruibo pharmaceutical and Beida Pharmaceutical Co., Ltd was successfully held in Hangzhou The two sides will rely on the strong R & D, production capacity and quality system of rybo pharmaceutical in starting raw materials, intermediates and APIs, as well as the R & D advantages of Beida pharmaceutical in innovative drug technology, work together to achieve mutual benefit and win-win results, and further promote the comprehensive strategic cooperation between the two sides Dawan Biology & Boji medicine in October, Dawan biology and Boji medicine reached a strategic cooperation, and the two sides signed a bilateral agreement on jointly developing a long-term biological new drug, gbb101 injection, which can resist renal function damage and lead to anemia Dr Chen Liang, co-founder and CEO of Dawan biology, said that the addition of Boji medicine will build a solid foundation for future clinical trials, bring common interests to both sides, and ensure good and high-quality results of clinical trials On December 20, 2019, Corning Jerry Pharma & TRACON and thinkti signed a partnership agreement with TRACON and thinkti to develop and commercialize the anticancer drug kn035 According to the agreement, TRACON is responsible for developing kn035 and commercializing it in the cooperation area at its own expense, while thoughtway and Jiangsu Corning Jerry are entitled to collect the royalties paid by TRACON in the amount of ten to the middle double digit percentage of the relevant net sales of kn035 Pfizer & theravance biopharma recently announced that Pfizer and theravance biopharma have jointly signed a global licensing agreement on the preclinical project of the skin targeting, local effect and rapid metabolism pan Janus kinase (Pan JAK) inhibitor of theravance biopharma Under the terms of the agreement, theravance biopharma will receive a $10 million cash advance and be eligible to receive up to $240 million in development and sales milestone payments from Pfizer It is also eligible for royalties based on net sales worldwide for any potential products generated by the project.